Non-steroidal SARMsSARMSelective androgen receptor modulator: a non-steroidal compound that binds the androgen receptor (the receptor for testosterone) and activates it to differing degrees depending on the tissue.
LGD-4033 vs S23 vs S4
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
LGD-4033 (Ligandrol) | S23 (Most Potent SARM) | S4 (Andarine, GTx-007) | |
|---|---|---|---|
| What it is | Experimental muscle-building SARM compound: muscle mass rose in small studies, but cases of liver injury are known; banned in sport. | Experimental SARM studied mainly in rats, unproven in humans; it shuts down the body’s own testosterone production and may damage the liver. | Experimental SARM that can cause yellow-tinted vision and night blindness; never approved as a medicine, with few studies in humans. |
| MechanismMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds). | Non-steroidal selective AR modulator (pyrrolidinecarboxamide). Strong AR agonist in muscle, moderate prostate activity. | Non-steroidal; binds the androgen receptor most strongly in its class | Androgen receptor modulator; also binds light-sensing proteins in the eye |
| Anabolic activity (Basaria 2013) | In healthy men, lean body mass rose by about 1.2 kg | — | — |
| Half-lifeHalf-lifeThe time for the compound’s plasma concentration to fall by half; indicates how fast it clears and how often it is dosed. | ~24-36 h (oral) | ~12 h (oral) | About 4 hours (oral; short) |
| OnsetOnsetThe time from dosing until a measurable effect appears. | 1-2 weeks (anecdotal strength gain) | 1-2 weeks | 1-2 weeks |
| Legal statusLegal / WADA statusThe compound’s regulatory status (e.g. prescription) and its place on the WADA prohibited-in-sport list. | Never an Rx. UGL 'research chemical'. WADA-banned S1.2 since 2008. | Never an Rx (Phase I never started in humans). UGL 'research chemical'. WADA-banned S1.2. | Never an Rx (GTx deprioritized after Phase II in 2010). UGL 'research chemical'. WADA-banned S1.2. |
| Anabolic activity (Jones 2009) | — | ~95% testosterone-level in vivo (rat bioassay). Higher than RAD-140. | — |
| Anabolic activity (Gao 2005) | — | — | In rat bioassay anabolic activity ~60-70% Test-level (in vivo) |
| Full entry | Open → | Open → | Open → |
What it is
LGD-4033 (Ligandrol)Experimental muscle-building SARM compound: muscle mass rose in small studies, but cases of liver injury are known; banned in sport.
S23 (Most Potent SARM)Experimental SARM studied mainly in rats, unproven in humans; it shuts down the body’s own testosterone production and may damage the liver.
S4 (Andarine, GTx-007)Experimental SARM that can cause yellow-tinted vision and night blindness; never approved as a medicine, with few studies in humans.
MechanismMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds).
LGD-4033 (Ligandrol)Non-steroidal selective AR modulator (pyrrolidinecarboxamide). Strong AR agonist in muscle, moderate prostate activity.
S23 (Most Potent SARM)Non-steroidal; binds the androgen receptor most strongly in its class
S4 (Andarine, GTx-007)Androgen receptor modulator; also binds light-sensing proteins in the eye
Anabolic activity (Basaria 2013)
LGD-4033 (Ligandrol)In healthy men, lean body mass rose by about 1.2 kg
S23 (Most Potent SARM)—
S4 (Andarine, GTx-007)—
Half-lifeHalf-lifeThe time for the compound’s plasma concentration to fall by half; indicates how fast it clears and how often it is dosed.
LGD-4033 (Ligandrol)~24-36 h (oral)
S23 (Most Potent SARM)~12 h (oral)
S4 (Andarine, GTx-007)About 4 hours (oral; short)
OnsetOnsetThe time from dosing until a measurable effect appears.
LGD-4033 (Ligandrol)1-2 weeks (anecdotal strength gain)
S23 (Most Potent SARM)1-2 weeks
S4 (Andarine, GTx-007)1-2 weeks
Legal statusLegal / WADA statusThe compound’s regulatory status (e.g. prescription) and its place on the WADA prohibited-in-sport list.
LGD-4033 (Ligandrol)Never an Rx. UGL 'research chemical'. WADA-banned S1.2 since 2008.
S23 (Most Potent SARM)Never an Rx (Phase I never started in humans). UGL 'research chemical'. WADA-banned S1.2.
S4 (Andarine, GTx-007)Never an Rx (GTx deprioritized after Phase II in 2010). UGL 'research chemical'. WADA-banned S1.2.
Anabolic activity (Jones 2009)
LGD-4033 (Ligandrol)—
S23 (Most Potent SARM)~95% testosterone-level in vivo (rat bioassay). Higher than RAD-140.
S4 (Andarine, GTx-007)—
Anabolic activity (Gao 2005)
LGD-4033 (Ligandrol)—
S23 (Most Potent SARM)—
S4 (Andarine, GTx-007)In rat bioassay anabolic activity ~60-70% Test-level (in vivo)
